Breast Cancer
Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates
Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.
Future Breast Cancer Treatments: A Focus on SIRDs, Biomarkers
Breast Cancer Challenges and Promises in Immunotherapy
Improving Access and Outcomes in HR+/HER2– Breast Cancer Treatment
Rise of Innovative Therapies for Breast Cancer Treatment
ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer
Navigating Breast Cancer Treatment Through Shared Decision-Making
Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies
Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor
Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors
More News
Managing Germline Mutations in Hereditary Breast Cancer Risk
